#USA #Pulsed Field Ablation #Del Medtech #Steven Mickelsen #Cardiff by the Sea

Introduction

Dr. Steven Mickelsen, a notable figure in electrophysiology and a pioneer in pulsed field ablation (PFA), recently announced an exciting new venture: the launch of Del Medtech Inc. This seed-stage medical device company is set to redefine minimally invasive ablation technology, moving its focus beyond cardiac care to address critical needs in various therapeutic fields.

The Mission of Del Medtech

The primary mission of Del Medtech Inc. is to develop innovative, single-use ablation devices. These devices are designed to enhance efficiency and patient outcomes in several areas, including:

• - Gastroenterology (GI)
• - Ear, Nose, and Throat (ENT)
• - Men’s and Women’s Health
• - Oncology

By targeting these sectors, Del Medtech is aiming to tap into an impressive market estimated to yield annual revenues between $1.4 billion to $7.4 billion, with growth rates projected between 9% and 13%.

Shaping the Future of Ablation Technologies

Dr. Mickelsen emphasizes the transformative potential of PFA technologies, which have made significant strides in catheter ablation over the past five years. He states, “It’s hard to ignore the transformative impact that PFA technologies have had.” Del Medtech Inc. will leverage this technology to tackle longstanding challenges faced in medical fields outside of cardiac treatment.

Presentation at LSI Emerging Medtech Summit

The company will share its vision during a presentation at the LSI Emerging Medtech Summit, taking place on September 8 in London. At this summit, global leaders in healthcare innovation will gather to discuss the future landscape of medical technology. Dr. Mickelsen is set to illustrate how Del Medtech is ready to lead the charge in ablation technologies similar to the rapid evolution recently witnessed in electrophysiology.

Invitation to Partners and Investors

Del Medtech is not only looking to innovate but is also eager to collaborate. Dr. Mickelsen is actively inviting investors and partners who want to engage in shaping the future of ablation therapies. He stated, “We are entering a period of rapid acceleration in ablative therapies” and emphasized how Del Medtech is well-positioned to spearhead this movement.

Conclusion

In conclusion, Del Medtech Inc. represents a bold step forward in the field of minimally invasive medicine, expanding the applications of pulsed field ablation technology. By focusing on several critical medical sectors, Dr. Mickelsen and his team are not just looking to enhance patient outcomes but are also poised to transform how ablation therapies are implemented across various specialties. As this company launches its journey, the involvement of like-minded partners and investors could be crucial in realizing its ambitious vision.

With the established success of PFA and the drive of Del Medtech, the future of minimally invasive treatments is certainly one to watch.